METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HYPOGLYCEMIA AND RELATED DISORDERS
A composition comprising chromium and insulin and/or a chromium-insulin complex, its method of preparation, and its use in the prevention and treatment of hypoglycemia and hypoglycemia-related conditions. This composition can be administered in numerous ways, including parenterally, intranasally, and orally. The composition stabilizes serum glucose levels and has a synergistic effect compared to chromium and insulin administered separately.
1 . A sterile injectable formulation comprising:
an amount of a chromium-insulin complex, the chromium-insulin complex having between 4 and 6 chromium ions per insulin hexamer; and
at least one excipient.
2 . The formulation of claim 1 , wherein the amount of the chromium-insulin complex is an amount sufficient to stabilize serum glucose levels in a patient in need thereof
3 . The formulation of claim 1 , wherein the sterile injectable pharmaceutical formulation provides greater therapeutic effect than an equivalent amount of injected insulin.
4 . The formulation of claim 1 , wherein the sterile injectable pharmaceutical formulation provides greater therapeutic effect than an equivalent amount of injected zinc-insulin.
5 . The formulation of claim 1 , wherein the chromium-insulin complex is dissolved in a solution.
6 . The formulation of claim 1 , wherein the chromium-insulin complex is suspended in a solution.
7 . The formulation of claim 1 , wherein the chromium-insulin complex has a molecular weight that is between about 30 kDa and 40 kDa.
8 . A method for reducing serum glucose levels in a subject in need thereof comprising:
providing an injectable chromium-insulin formulation; and
administering the composition to the subject, wherein the administration reduces serum glucose levels in the subject to a great extent after one hour than an equivalent amount of an injectable insulin formulation or injectable zinc-insulin formulation.
9 . The method of claim 8 , further comprising identifying the patient in need of reduced serum glucose levels.
10 . The method of claim 8 , wherein the injectable chromium-insulin formulation includes chromium-insulin complexes, the chromium-insulin complexes having between 4 and 6 chromium ions per insulin hexamer.
11 . A method for reducing serum glucose levels in a subject having diabetes comprising:
providing an injectable chromium-insulin formulation; and
administering the composition to the subject having diabetes, wherein the administration reduces serum glucose levels in the subject to a great extent after three hours than an equivalent amount of an injectable insulin formulation or injectable zinc-insulin formulation.
12 . The method of claim 11 , further comprising identifying the subject having diabetes.
13 . The method of claim 11 , wherein the injectable chromium-insulin formulation includes chromium-insulin complexes, the chromium-insulin complexes having between 4 and 6 chromium ions per insulin hexamer.
14 . A method for increasing serum insulin levels in a subject in need thereof comprising:
providing an injectable chromium-insulin formulation; and
administering the composition to a subject, wherein the administration increases serum insulin levels in the subject to a great extent after thirty minutes than an equivalent amount of an injectable insulin formulation or injectable zinc-insulin formulation.
15 . The method of claim 14 , further comprising identifying a patient in need of increased serum insulin levels.
16 . The method of claim 14 , wherein the injectable chromium-insulin formulation includes chromium-insulin complexes, the chromium-insulin complexes having between 4 and 6 chromium ions per insulin hexamer.
17 . A method for increasing serum insulin levels in a subject having diabetes comprising:
providing an injectable chromium-insulin formulation; and
administering the composition to the subject having diabetes, wherein the administration increases serum levels in the subject to a great extent after one hour than an equivalent amount of an injectable insulin formulation or injectable zinc-insulin formulation.
18 . The method of claim 17 , further comprising identifying the patient having diabetes.
19 . The method of claim 17 , wherein the injectable chromium-insulin formulation includes chromium-insulin complexes, the chromium-insulin complexes having between 4 and 6 chromium ions per insulin hexamer.